Received: 18 January 2019
Accepted: 17 April 2019
First Online: 3 June 2019
Ethics approval and consent to participate
: The study was approved by the University Health Network Research Ethics Board, with a waived requirement for informed consent due to the retrospective nature of the analysis.
: Not applicable.
: SB and TM report that their institution has been paid by Insmed for their involvement in a randomized clinical trial of inhaled amikacin for NTM lung disease, outside the submitted work. TM reports that his institution has been paid for his consultative and/or educational services from Insmed, Astra-Zeneca, RedHill and Horizon, all outside the submitted work. SB reports that her institution has been paid for her consultative and/or educational services from Boehringer Ingelheim, outside the submitted work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.